Axonics, Inc. (AXNX) Tops Q4 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results
March 1, 2023 4:01 PM ESTGenerated record quarterly revenue of $86 million, an increase of 62% y/y
Reported fiscal year 2022 revenue of $274 million, an increase of 52% y/y
Reiterated fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022.
This quarters record results... More



